Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS-Cov-2 Clear all
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 26, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

NCT04349371
View directory record Official record
Conditions
COVID, Coronavirus Infection
Interventions
Chloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

NCT04362137
View directory record Official record
Conditions
Cytokine Storm (Covid-19)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 26, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation

NCT05364268
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Coronavirus Disease 2019, Coronavirus Disease-19, SARS-CoV-2 Infection
Interventions
Diagnostic Test: Diagnostic Software as Medical Device
Device
Lead sponsor
AudibleHealth AI, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
514 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Sunrise, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 26, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

NCT05087524
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
BinaxNOW Ag Card
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 26, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 and SARS-CoV-2 Detection in Saliva

NCT04517682
View directory record Official record
Conditions
RNA Virus Infections
Interventions
RT-PCR
Diagnostic Test
Lead sponsor
Ambry Genetics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aliso Viejo, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 26, 2026, 5:01 AM EDT
Completed No phase listed Observational

Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)

NCT04350073
View directory record Official record
Conditions
COVID-19
Interventions
Q-NRG Metobolic Cart Device, MuscleSound Ultrasound, Multifrequency Bioimpedance Spectroscopy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)

NCT05910879
View directory record Official record
Conditions
Health Behavior, Health Care Utilization, Vaccine Hesitancy
Interventions
Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

NCT05975060
View directory record Official record
Conditions
COVID-19
Interventions
XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 54 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)

NCT05178173
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, SARS CoV 2 Infection
Interventions
Placebo Comparator: Sterile Water, 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

NCT06437223
View directory record Official record
Conditions
Long COVID
Interventions
Tonabersat, Placebo
Drug
Lead sponsor
Inflammx Therapeutics Inc
Industry
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

NCT05596734
View directory record Official record
Conditions
Influenza, Human, COVID-19
Interventions
bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
59
States / cities
Athens, Alabama • Phoenix, Arizona • Lake Forest, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

NCT04551911
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions
Rayaldee, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Results available

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
View directory record Official record
Conditions
Viral Disease
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Mountain View, California • Newport Beach, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 26, 2026, 5:01 AM EDT
Withdrawn Not applicable Interventional

Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients

NCT04480411
View directory record Official record
Conditions
Diagnoses Disease, Covid19
Interventions
Doctorgram Patient Kit
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 26, 2026, 5:01 AM EDT
Active, not recruiting No phase listed Observational

COVID-19 Biorepository

NCT04568148
View directory record Official record
Conditions
Covid-19, SARS-CoV 2, Coronavirus, COVID
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 26, 2026, 5:01 AM EDT
Completed No phase listed Observational Results available

A Prospective "Universal" Observational Database for COVID-19

NCT04347993
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Not listed
Enrollment
4,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 26, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05633407
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod, Placebo
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 26, 2026, 5:01 AM EDT
Not yet recruiting Phase 2 Interventional

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Long COVID
Interventions
Valacyclovir, Celecoxib, Paxlovid, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 5:01 AM EDT